Loading clinical trials...
Loading clinical trials...
This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT04569591 · Cushing's Disease, Pituitary Adenoma
NCT03346954 · Cushing's Disease
NCT03111810 · Iatrogenic Cushing's Disease
NCT00612066 · Cushing's Disease
NCT00889525 · Cushing's Disease, Corticotroph Adenoma
Stanford University Medical Center Stanford Cancer Center (3)
Stanford, California
University Chicago Hospital Dept. of Univ of Chicago
Chicago, Illinois
Dana Farber Cancer Institute The Melanoma Program
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions